Cell Therapeutics Announces Agreement For Phase II Study Of Pixantrone In Metastatic
 

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) (the "Company") announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens...

More...